Phase II Study of AZD9291 in Patients With Advanced Stage Non-small Cell Lung Cancer Following Prior EGFR TKI Therapy With EGFR and T790M Mutations Detected in Plasma Circulating Tumor DNA (PLASMA)
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PLASMA
- 21 Jul 2017 Planned End Date changed from 1 Jun 2020 to 24 Feb 2020.
- 21 Jul 2017 Planned primary completion date changed from 1 Jun 2019 to 24 Feb 2019.
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.